# Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

> **NCT00162136** · PHASE1 · COMPLETED · sponsor: **R-Pharm** · enrollment: 35 (actual)

## Conditions studied

- Solid Malignancies

## Interventions

- **DRUG:** Ixabepilone

## Key facts

- **NCT ID:** NCT00162136
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162136, "Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00162136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*